Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Rande Is . . . HOME -- Ignore unavailable to you. Want to Upgrade?

To: Rande Is who wrote (28463)	6/24/2000 11:16:00 AM
From: Rick Buskey	Respond to of 57584

LPTHA--found this posting for anyone looking for a little write-up. individualinvestor.com

To: Rande Is who wrote (28463)	6/24/2000 11:22:00 AM
From: Rick Buskey	Respond to of 57584

Rande-Read this-Nice writeup on the Gene. and Bio. sectors.While I hold MLNM and HGSI in my long term port.----once the news of the Mapping ,etc-(all the hype-mag.,write-ups,newspapers)hits-----maybe it would be best to take profits.This sector was hot,then got hammered,now is on its way up again.While i do believe in the long term promise for the stocks in the sector-----maybe the short term news is already built into the prices.I wonder if I should take my profits off the table and wait to buy back later when the sector cools off and nobody wants to own the stocks anymore-if you know what I mean. Just a thought---I think we will head higher for a little while longer though-----thinking about it............Rick

To: Rande Is who wrote (28463)	6/24/2000 11:24:00 AM
From: MSo	Respond to of 57584

Great post and analysis of potential trends; don't know if you watched Charlie Rose's programs this week - featured variety of leading lights in genome, biotech, DNA fields - extraordinary times, though breakthroughs will be stunning, they may also take some time, as the permutations to compute through are quite staggering.

To: Rande Is who wrote (28463)	6/24/2000 1:39:00 PM
From: American Spirit	Respond to of 57584

This is what I mean about retail bargains now. I'm long and holding GPS, ANF, TOM and COST all sitting at bottom range. Friday June 23, 4:48 pm Eastern Time Morningstar.com Gap Stock Looks Like A Screaming Buy By Mark A. Sellers Shares of the Gap (NYSE: GPS - news) may be down, but they're not out. In fact, at current levels they look like a screaming buy. Short-term problems are to blame for the stock's recent decline, and when these problems clear up, the stock should bounce back. At current levels, investors have the chance to buy one of the great retail stocks of the past decade at a very reasonable price. The shares hit a new 52-week low this week, bottoming out at $28. The stock now has a P/E of just under 23, slightly above the apparel industry average of 20. However, there are some important differences between the Gap and its retail brethren such as Pacific Sunwear (Nasdaq: PSUN - news), American Eagle (Nasdaq: AEOS - news), Limited (NYSE: LTD - news), Abercrombie & Fitch (NYSE: ANF - news), and Tommy Hilfiger (NYSE: TOM - news). For one, the Gap has a very long history of consistent growth that outpaces most of its industry peers. During the past 10 years, the company has a compound annual growth rate in revenues and earnings per share of 22% and 29%, respectively. Also during this time period, gross margins excluding depreciation and amortization have increased from 39.6% to 45.3%, and net margins have grown from 7.5% to about 10%. Gap management has also done a great job of controlling asset efficiency, with a 22% return on assets and 50.5% return on equity last year. In fact, return on equity has averaged a hefty 37.5% over the past five years, versus 22% for the S&P 500. But bears argue same-store sales growth has declined 2% this year, indicating the company may be reaching maturity and be in the beginnings of a slower-growth phase. However, there's still a lot of room for the company to grow. For instance, only about 13% of its stores are located outside the U.S., where its market share is less than 1%. Recent ``fashion mistakes'' have impacted Gap's results this year, causing inventories to rise, but CEO Mickey Drexler has a strong track record of keeping his finger on the pulse of the American consumer, so this problem should be short lived. With a seasoned management team, a consistent track record, a well-known brand name, and international expansion opportunities, there are a lot of reasons for investors to like the Gap.

To: Rande Is who wrote (28463)	6/25/2000 1:14:00 AM
From: Mike McFarland	Read Replies (2) \| Respond to of 57584

Sounds like you've been keeping tabs on the genome news lately. I saw Venter on the Charlie Rose show on Monday, Collins was a good interview on Tuesday...taped the rest of the week. I'm not much for the billion dollar genomics stocks, kinda hard to assess what they're up to. What I am excited about is watching the old plain vanilla biotechs tap into this information--if the information is useful they'll know how to mine it for all it is worth. On the other hand, I own several biotechs that probably have no interest in genome data. What they probably need is very specific gene expresson data. Just throwing some thoughts out there. In your Ragingbull post, you wrote We need to watch for alliances, mergers and other consolidations that could set up a formidable opponent to the tradtional chemical drug makers. I think the most recent was that AVE/MLNM deal. Wow, to think that Hoechst could simply have bought out Millennium a couple years ago for that kind of money! (although they might not have sold out) Although the genome stocks look richly priced to me, who the hell am I to judge? And you could say that if companies like CRA start pulling billion dollar drugs out of the genome the valuation is okay. And it isn't as if Celera's business can be replaced by a bootlegged DVD of sequence-- they're supposed to be adding value, using some sort of mathmatical algorithms to identify the genes where are not yet known, right? Fill us in Rande, I don't follow CRA. I do own some Genset, but it has lagged the group badly for no reason that I can see other than it doesn't do a lot of trading volume and hasn't had the sexy news flow.